160 related articles for article (PubMed ID: 22333263)
21. Everolimus-related pulmonary toxicity in heart transplant recipients.
Expósito V; de Prada JA; Gómez-Román JJ; González-Vilchez F; Llano-Cardenal M; García-Camarero T; Fernández-Valls M; Ruano J; Martín-Durán R
J Heart Lung Transplant; 2008 Jul; 27(7):797-800. PubMed ID: 18582812
[TBL] [Abstract][Full Text] [Related]
22. A drug safety evaluation of everolimus in kidney transplantation.
Holdaas H; Midtvedt K; Åsberg A
Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
[TBL] [Abstract][Full Text] [Related]
23. Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity.
Feagans J; Victor D; Moehlen M; Florman SS; Regenstein F; Balart LA; Joshi S; Killackey MT; Slakey DP; Paramesh AS
J La State Med Soc; 2009; 161(3):166, 168-72. PubMed ID: 19772040
[TBL] [Abstract][Full Text] [Related]
24. Reversible sirolimus-associated pneumonitis after heart transplantation.
Hamour IM; Mittal TK; Bell AD; Banner NR
J Heart Lung Transplant; 2006 Feb; 25(2):241-4. PubMed ID: 16446228
[TBL] [Abstract][Full Text] [Related]
25. Long-term use of everolimus in lung transplant patients.
Parada MT; Alba A; Sepúlveda C; Melo J
Transplant Proc; 2011; 43(6):2313-5. PubMed ID: 21839261
[TBL] [Abstract][Full Text] [Related]
26. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
[TBL] [Abstract][Full Text] [Related]
27. Plasma neutrophil gelatinase-associated lipocalin and worsening renal function during everolimus therapy after heart transplantation.
Imamura T; Kinugawa K; Doi K; Hatano M; Fujino T; Kinoshita O; Nawata K; Noiri E; Kyo S; Ono M
Int Heart J; 2015; 56(1):73-9. PubMed ID: 25742944
[TBL] [Abstract][Full Text] [Related]
28. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
29. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
30. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
[TBL] [Abstract][Full Text] [Related]
31. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus-associated diffuse alveolar hemorrhage.
Vlahakis NE; Rickman OB; Morgenthaler T
Mayo Clin Proc; 2004 Apr; 79(4):541-5. PubMed ID: 15065619
[TBL] [Abstract][Full Text] [Related]
33. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
[TBL] [Abstract][Full Text] [Related]
34. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
Saito Y; Nagayama M; Miura Y; Ogushi S; Suzuki Y; Noro R; Minegishi Y; Kimura G; Kondo Y; Gemma A
Jpn J Clin Oncol; 2013 May; 43(5):559-62. PubMed ID: 23423809
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
37. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study.
Spagnoletti G; Favi E; Gargiulo A; Salerno MP; Citterio F
Transplant Proc; 2011 May; 43(4):1010-2. PubMed ID: 21620038
[TBL] [Abstract][Full Text] [Related]
38. Severe everolimus-associated pneumonitis in a renal transplant recipient.
Alexandru S; Ortiz A; Baldovi S; Milicua JM; Ruíz-Escribano E; Egido J; Plaza JJ
Nephrol Dial Transplant; 2008 Oct; 23(10):3353-5. PubMed ID: 18658177
[TBL] [Abstract][Full Text] [Related]
39. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
White DA; Camus P; Endo M; Escudier B; Calvo E; Akaza H; Uemura H; Kpamegan E; Kay A; Robson M; Ravaud A; Motzer RJ
Am J Respir Crit Care Med; 2010 Aug; 182(3):396-403. PubMed ID: 20194812
[TBL] [Abstract][Full Text] [Related]
40. Acute respiratory distress attributed to sirolimus in solid organ transplant recipients.
Wang WL; Yu LX
Am J Emerg Med; 2015 Jan; 33(1):124.e1-4. PubMed ID: 24993686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
